Cover Image
Market Research Report
Product code
1031978

Global Constrained Peptide Drugs Market: Focus on Peptide Type, Product, and Country Analysis - Analysis and Forecast, 2023-2031

Published: | BIS Research Inc. | 163 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Constrained Peptide Drugs Market: Focus on Peptide Type, Product, and Country Analysis - Analysis and Forecast, 2023-2031
Published: October 11, 2021
BIS Research Inc.
Content info: 163 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

“Global Constrained Peptide Drugs Market to Reach $10,367.2 Million by 2031.”

Market Report Coverage - Constrained Peptide Drugs

Market Segmentation

  • Product: BT1718, BT5528, Zilucoplan (RA101495), Rusfertide (PTG-300), PN-943
  • Peptide Type: Cyclic Peptides, Disulfide-Rich Peptides (DRPs)
  • Region: North America, Europe, Asia-Pacific

Regional Segmentation

  • North America - U.S. and Canada
  • Europe - U.K., Germany, France, Italy, and Spain
  • Asia-Pacific - Japan

Market Growth Drivers

  • Enhanced Binding Affinity and Cellular Uptake
  • Development of Synthetic Constraining Methods
  • Limitations with Conventional Peptides
  • Increasing Government and Private Funding

Market Challenges

  • Increased Competition from Biologics
  • Risk of Immunogenic Effects and Unsatisfactory ADME Properties

Market Opportunities

  • Role of Constrained Peptides in Drug Discovery
  • Various Application in CNS Disease Studies and Anti-Cancer Therapy

Key Companies Profiled

Aileron Therapeutics, Inc, Bicycle Therapeutics, PLC, Polyphor Limited, Protagonist Therapeutics, Inc, Santhera Pharmaceuticals Holding, Union Chimique Belge S.A. (UCB), Pepscan Therapeutics B.V., Pepticom Ltd., PeptiDream, Inc., CPC Scientific Inc., Creative Peptides, Bio-Synthesis Inc.

Key Questions Answered in this Report:

  • What are constrained peptides?
  • How are constrained peptide drugs developed?
  • What are the potential indications targeted using constrained peptide drugs?
  • What are emerging constrained peptide drugs?
  • How does the pipeline for the global constrained peptide drugs market look like?
  • What is the market size and future potential of constrained peptide drugs?
  • What are the major market drivers, challenges, and opportunities in the global constrained peptide drugs market?
  • What is the mechanism of action of constrained peptides?
  • What changes in dose administration are being tried the most in pipeline products?
  • How does the clinical trial landscape look for the global constrained peptide drugs market?
  • What will be the impact of COVID-19 on this market?
  • What is the forecast revenue of the global constrained peptide drugs market (by peptide type)?
  • Which region is expected to contribute to the highest revenue of the global constrained peptide drugs market during the forecast period?

Market Overview

The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to reach $10,367.2 million by 2031, witnessing a CAGR of 90.37% during the forecast period 2023-2031. The market growth in revenue is largely fueled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period.

Competitive Landscape

The global constrained peptide drugs market comprises several companies established in the past decade. The increase in need of unmet clinical need, cost-effective treatment, innovative route of administration, and numerous biological intervention opportunities can be considered as the key factors driving the global constrained peptide drugs market. Analysis of the key strategies incorporated by the players of the global constrained peptide drugs market suggest pipeline constrained peptides as priority product in the portfolio. The companies are tapping the opportunity to incessantly evolve constrained peptides as best-in-class treatments for a wide therapeutic spectrum. In the past four years, key market players in the global constrained peptide drugs market have witnessed nine regulatory and legal activities, nine synergistic activities, 28 clinical developments, two mergers and acquisitions, and 28 funding activities.

Table of Contents
Product Code: BHL1127SA

Table of Contents

1 Definition

  • 1.1 Inclusion and Exclusion Criteria

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Constrained Peptides: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Markets Overview

  • 4.1 Introduction
    • 4.1.1 Structure and Design of Constrained Peptides
    • 4.1.2 Types of Constrained Peptides
  • 4.2 Evolution of Constrained Peptides
  • 4.3 Development of Constrained Peptides as Drugs
  • 4.4 Global Constrained Peptide Drugs Market and Growth Potential, $Million, 2023-2031

5 Characteristics of Conformationally Constrained Peptides

  • 5.1 Properties of Conformationally Constrained peptides
  • 5.2 Synthesis of Constrained Peptides
    • 5.2.1 Chemical Peptide Ligation and Bridging
    • 5.2.2 Chemical Linkage of Peptides onto Scaffolds (CLIPS)
    • 5.2.3 Peptide Stapling
    • 5.2.4 Peptide Discovery Platform System (PDPS)
    • 5.2.5 Liquid Phase Peptide Synthesis (LPPS)
    • 5.2.6 Solid Phase Peptide Synthesis (SPPS)
  • 5.3 Advances in Peptide Technology
  • 5.4 Peptide Display and Selection System

6 Pipeline

  • 6.1 Constrained Peptide Drugs Pipeline Analysis
  • 6.2 Constrained Peptide Drugs Clinical Trial Design
    • 6.2.1 Zilucoplan (RA101495)
      • 6.2.1.1 Product Profile
      • 6.2.1.2 Zilucoplan (RA101495) Phase III Study Design
      • 6.2.1.3 Zilucoplan Efficacy, Safety, and Tolerability (Phase II)
      • 6.2.1.4 Zilucoplan Pharmacokinetics and Pharmacodynamics Profile (Phase I)
    • 6.2.2 BT1718
      • 6.2.2.1 Product Profile
      • 6.2.2.2 BT1718 Preclinical Studies
      • 6.2.2.3 BT1718 Phase I/IIa Clinical Study Design
    • 6.2.3 BT5528
      • 6.2.3.1 Product Profile
      • 6.2.3.2 BT5528 Preclinical Studies
      • 6.2.3.3 BT5528 Phase I/II Clinical Study Design
    • 6.2.4 Rusfertide (PTG-300)
      • 6.2.4.1 Product Profile
      • 6.2.4.2 Rusfertide (PTG-300) Ongoing Phase II Clinical Study Design
      • 6.2.4.3 Rusfertide (PTG-300) Clinical Development Program in Hereditary Hemochromatosis (HH)
    • 6.2.5 PN-943
      • 6.2.5.1 Product Profile
      • 6.2.5.2 PN-943 Preclinical Proof-of-Concept Studies
      • 6.2.5.3 PN-943 Phase I Clinical Trial Design
      • 6.2.5.4 PN-943 Phase II Ideal Clinical Study Design in Ulcerative Colitis

7 Impact of COVID-19 on Global Constrained Peptide Drugs Market

  • 7.1 Impact on Constrained Peptide Drugs Companies
  • 7.2 Clinical Trial Disruptions and Resumptions

8 Industry Insights

  • 8.1 Overview
  • 8.2 Challenges in Constrained Peptides Regulatory Approval Pathway
  • 8.3 Regulatory Scenario of Constrained Peptides
  • 8.4 Legal Requirements and Frameworks in the U.S.
    • 8.4.1 Clinical Trial Authorization
    • 8.4.2 Marketing Authorization
    • 8.4.3 U.S. FDA Guidelines for NDA Submission
    • 8.4.4 Post-Authorization Regulations
  • 8.5 Legal Requirements and Frameworks in Europe
    • 8.5.1 EMA Drug License Application Process
    • 8.5.2 Centralized Procedure
    • 8.5.3 Decentralized Procedure
    • 8.5.4 Mutual-Recognition Procedure
    • 8.5.5 National Procedure
  • 8.6 Legal Requirements and Frameworks in Asia-Pacific
    • 8.6.1 Legal Requirements and Frameworks in Japan

9 Market Dynamics

  • 9.1 Impact Analysis
  • 9.2 Market Drivers
    • 9.2.1 Enhanced Binding Affinity and Cellular Uptake
    • 9.2.2 Development of Synthetic Constraining Methods
    • 9.2.3 Limitations with Conventional Peptides
    • 9.2.4 Increasing Government and Private Funding
      • 9.2.4.1 Funding by Private Companies
      • 9.2.4.2 Funding by Public Companies
      • 9.2.4.3 Funding by Government Institutions
  • 9.3 Market Restraints
    • 9.3.1 Increased Competition from Biologics
    • 9.3.2 Risk of Immunogenic Effects and Unsatisfactory ADME Properties
  • 9.4 Market Opportunities
    • 9.4.1 Role of Constrained Peptides in Drug Discovery
    • 9.4.2 Various Application in CNS Disease Studies and Anti-Cancer Therapy

10 Market Analysis

  • 10.1 Global Constrained Peptide Drugs Market (by Peptide Type), $Million, 2023-2031
    • 10.1.1 Overview
    • 10.1.2 Cyclic Peptides
    • 10.1.3 Disulfide-Rich Peptides (DRPs)
  • 10.2 Global Constrained Peptide Drugs Market (by Product), $Million, 2023-2031
    • 10.2.1 Overview
    • 10.2.2 BT1718
    • 10.2.3 BT5528
    • 10.2.4 Zilucoplan (RA101495)
    • 10.2.5 Rusfertide (PTG-300)
    • 10.2.6 PN-943
  • 10.3 Global Constrained Peptide Drugs Market (by Country), $Million, 2023-2031
    • 10.3.1 North America
      • 10.3.1.1 U.S.
      • 10.3.1.2 Canada
    • 10.3.2 Europe
      • 10.3.2.1 U.K.
      • 10.3.2.2 Germany
      • 10.3.2.3 France
      • 10.3.2.4 Italy
      • 10.3.2.5 Spain
    • 10.3.3 Asia-Pacific
      • 10.3.3.1 Japan

11 Markets - Competitive Benchmarking & Company Profiles

  • 11.1 Competitive Landscape
    • 11.1.1 Key Developments
    • 11.1.2 Regulatory and Legal Activities
    • 11.1.3 Mergers and Acquisitions
    • 11.1.4 Synergistic Activities
    • 11.1.5 Funding Activities
    • 11.1.6 Clinical Developments
  • 11.2 Company Profiles
    • 11.2.1 Overview
  • 11.3 Aileron Therapeutics, Inc
    • 11.3.1 Company Overview
    • 11.3.2 Role of Aileron Therapeutics, Inc in the Global Constrained Peptide Drugs Market
    • 11.3.3 R&D Analysis
    • 11.3.4 SWOT Analysis
  • 11.4 Bicycle Therapeutics, PLC
    • 11.4.1 Company Overview
    • 11.4.2 Role of Bicycle Therapeutics, PLC in the Global Constrained Peptide Drugs Market
    • 11.4.3 Collaboration with Biopharmaceutical Companies
    • 11.4.4 R&D Analysis
    • 11.4.5 SWOT Analysis
  • 11.5 Polyphor Limited
    • 11.5.1 Company Overview
    • 11.5.2 Role of Polyphor Limited in the Global Constrained Peptide Drugs Market
    • 11.5.3 Collaboration with Research Institutions and Biopharmaceutical Companies
    • 11.5.4 Financials
    • 11.5.5 R&D Analysis
    • 11.5.6 SWOT Analysis
  • 11.6 Protagonist Therapeutics, Inc
    • 11.6.1 Company Overview
    • 11.6.2 Role of Protagonist Therapeutics, Inc in the Global Constrained Peptide Drugs Market
    • 11.6.3 Collaboration with Biopharmaceutical Companies
    • 11.6.4 Financials
    • 11.6.5 R&D Analysis
    • 11.6.6 SWOT Analysis
  • 11.7 Santhera Pharmaceuticals Holding
    • 11.7.1 Company Overview
    • 11.7.2 Role of Santhera Pharmaceuticals Holding in the Global Constrained Peptide Drugs Market
    • 11.7.3 Financials
    • 11.7.4 SWOT Analysis
  • 11.8 Union Chimique Belge S.A. (UCB)
    • 11.8.1 Company Overview
    • 11.8.2 Role of Union Chimique Belge S.A. in the Global Constrained Peptide Drugs Market
    • 11.8.3 Financials
    • 11.8.4 R&D Analysis
    • 11.8.5 SWOT Analysis
  • 11.9 Pepscan Therapeutics B.V.
    • 11.9.1 Company Overview
    • 11.9.2 Role of Pepscan Therapeutics B.V. in the Global Constrained Peptide Drugs Market
  • 11.1 Pepticom Ltd.
    • 11.10.1 Company Overview
    • 11.10.2 Role of Pepticom Ltd. in the Global Constrained Peptide Drugs Market
  • 11.11 PeptiDream, Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Role of PeptiDream, Inc. in the Global Constrained Peptide Drugs Market
  • 11.12 CPC Scientific Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Role of CPC Scientific Inc. in the Global Constrained Peptide Drugs Market
  • 11.13 Creative Peptides
    • 11.13.1 Company Overview
    • 11.13.2 Role of Creative Peptides in the Global Constrained Peptide Drugs Market
  • 11.14 Bio-Synthesis Inc
    • 11.14.1 Company Overview
    • 11.14.2 Role of Bio-Synthesis Inc in the Global Constrained Peptide Drugs Market

List of Figures

  • Figure 1: Peptide-Based Drugs Approved by the U.S. FDA (2015-2019)
  • Figure 2: Constrained Peptide Drugs Global Clinical Trials (by Phase), 2021
  • Figure 3: Constrained Peptide Drugs Global Clinical Trial (by Indication), 2021
  • Figure 4: Global Constrained Peptide Drugs Market Growth Revenue, $Million, 2023-2031
  • Figure 5: Global Constrained Peptide Drugs: Impact Analysis
  • Figure 6: Revenue Contribution of Different Segments, 2023, 2025, and 2031
  • Figure 7: Global Constrained Peptide Drugs Market (by Product)
  • Figure 8: Global Constrained Peptide Drugs Market (by Region), $Million, 2023-2031
  • Figure 9: Global Constrained Peptide Drugs Market Segmentation
  • Figure 10: Global Constrained Peptide Drugs Methodology
  • Figure 11: Primary Research Methodology
  • Figure 12: Epidemiology-Based Approach
  • Figure 13: Inducing Conformational Effects
  • Figure 14: Two Main Types of Constraints
  • Figure 15: Methodology for Restricting Conformation in Peptides
  • Figure 16: Types of Constrained Peptides
  • Figure 17: Key Milestones in Evolution of Constrained Peptides
  • Figure 18: Major Factors Affecting Constrained Peptide Development
  • Figure 19: Peptide-Based Drugs Approved by the U.S. FDA (2015-2019)
  • Figure 20: Global Constrained Peptide Drugs Market Growth Revenue, $Million, 2023-2031
  • Figure 21: Synthesis of Constrained Peptides using Chemical Peptide Ligation and Bridging
  • Figure 22: Constrained Peptide Synthesis using CLIPS Technology
  • Figure 23: Constrained Peptides Synthesis using Peptide Stapling
  • Figure 24: Peptide Discovery Platform System (PDPS) Technology
  • Figure 25: Synthesis of Peptides Using Liquid Phase Peptide Synthesis
  • Figure 26: Synthesis of Peptides Using Solid Phase Peptide Synthesis
  • Figure 27: Companies and Their Proprietary Technologies
  • Figure 28: Phage Display Technology
  • Figure 29: Constrained Peptide Drugs Global Clinical Trials (by Phase), 2021
  • Figure 30: Constrained Peptide Drugs Global Clinical Trials (by Indication), 2021
  • Figure 31: Zilucoplan (RA101495) Mechanism of Action
  • Figure 32: Zilucoplan Phase III Clinical Trial Design for Generalized Myasthenia Gravis
  • Figure 33: Zilucoplan Phase II Clinical Trial Design for Generalized Myasthenia Gravis
  • Figure 34: Zilucoplan Safety and Efficacy Tolerability Profile
  • Figure 35: Zilucoplan PK/PD Profile Results
  • Figure 36: Illustration of BT1718
  • Figure 37: High MT1-MMP Expressing Tumors Examples
  • Figure 38: BT1718 Preclinical Studies Framework
  • Figure 39: BT1718 Phase I Portion Clinical Study
  • Figure 40: BT1718 Phase IIa Portion Clinical Study
  • Figure 41: Illustration of BT5528
  • Figure 42: Tumors with EphA2 overexpression
  • Figure 43: BT5528 Preclinical Studies Framework
  • Figure 44: BT5528 Phase I Portion Clinical Study
  • Figure 45: Limited Current Treatment Options in Polycythemia Vera
  • Figure 46: Rusfertide (PTG-300) Phase II clinical Design for Polycythemia Vera
  • Figure 47: Clinical Proof-of-Concept Study Intervention Model Design
  • Figure 48: Updated Results from Ongoing Phase II Clinical Study
  • Figure 49: Clinical Proof-of-Concept Study Intervention Model Design for HH
  • Figure 50: Results from PN-943 Phase I Clinical Trial
  • Figure 51: PN-943 Phase II Ongoing Clinical Study Design
  • Figure 52: PN-943 Phase II IDEAL Study Intervention Model Design
  • Figure 53: Clinical Trial Authorization for Constrained Peptides in the U.S.
  • Figure 54: Steps for Obtaining Marketing Authorization
  • Figure 55: U.S. FDA Review Timeline
  • Figure 56: EMA Review Timeline
  • Figure 57: Factors Affecting Constrained Peptide Cellular Penetration
  • Figure 58: Key Innovative Modern Technologies and Constraining Methods
  • Figure 59: Properties of Traditional Peptides Vs. Constrained Peptides
  • Figure 60: Revenue Contribution of Different Segments, 2023, 2025, and 2031
  • Figure 61: Global Constrained Peptide Drugs Market (Cyclic Peptides), $Million, 2023-2031
  • Figure 62: Global Constrained Peptide Drugs Market (Disulfide-Rich Peptides), $Million, 2025-2031
  • Figure 63: Global Constrained Peptide Drugs Market (by Product)
  • Figure 64: Global Revenue for BT1718, $Million, 2025-2031
  • Figure 65: Global Revenue for BT5528, $Million, 2027-2031
  • Figure 66: Global Revenue for Zilucoplan (RA101495), $Million, 2023-2031
  • Figure 67: Global Revenue for Rusfertide (PTG-300), $Million, 2025-2031
  • Figure 68: Global Revenue for PN-943, $Million, 2026-2031
  • Figure 69: Global Constrained Peptide Drugs Market (by Region)
  • Figure 70: Global Constrained Peptide Drugs Market (by Region), $Million, 2023-2031
  • Figure 71: North America Constrained Peptide Drugs Market, $Million, 2023-2031
  • Figure 72: North America: Market Dynamics
  • Figure 73: North America Constrained Peptide Drugs Market (by Country), $Million, 2023 and 2031
  • Figure 74: U.S. Constrained Peptide Drugs Market, $Million, 2023-2031
  • Figure 75: Canada Constrained Peptide Drugs Market, $Million, 2023-2031
  • Figure 76: Europe Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 77: Europe: Market Dynamics
  • Figure 78: Europe Constrained Peptide Drugs Market (by Country), $Million, 2025 and 2031
  • Figure 79: U.K. Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 80: Germany Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 81: France Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 82: Italy Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 83: Spain Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 84: Japan Constrained Peptide Drugs Market, $Million, 2025-2031
  • Figure 85: Share of Key Developments and Strategies, January 2018-July 2021
  • Figure 86: Share of Regulatory and Legal Activities (by Company), January 2018-July 2021
  • Figure 87: Share of Mergers and Acquisitions (by Company), January 2018-July 2021
  • Figure 88: Share of Synergistic Activities (by Company), January 2018-July 2021
  • Figure 89: Share of Funding Activities (by Company), January 2018-July 2021
  • Figure 90: Share of Clinical developments (by Company), January 2018-July 2021
  • Figure 91: Aileron Therapeutics, Inc: Product Portfolio
  • Figure 92: Aileron Therapeutics, Inc: Overall R&D Expenditure, 2019-2020
  • Figure 93: Aileron Therapeutics, Inc: SWOT Analysis
  • Figure 94: Bicycle Therapeutics, PLC: Product Portfolio
  • Figure 95: Bicycle Therapeutics, PLC Collaboration with Biopharmaceutical Companies
  • Figure 96: Bicycle Therapeutics, PLC: Overall R&D Expenditure, 2018-2020
  • Figure 97: Bicycle Therapeutics, PLC: SWOT Analysis
  • Figure 98: Polyphor Limited: Product Portfolio
  • Figure 99: Polyphor Limited Collaboration with Research Institutions and Biopharmaceutical Companies
  • Figure 100: Polyphor Limited: Overall Financials, 2018-2020
  • Figure 101: Polyphor Limited: Revenue (by Region), 2018-2020
  • Figure 102: Polyphor Limited: Overall R&D Expenditure, 2018-2020
  • Figure 103: Polyphor Limited: SWOT Analysis
  • Figure 104: Protagonist Therapeutics, Inc: Product Portfolio
  • Figure 105: Protagonist Therapeutics, Inc Collaboration with Biopharmaceutical Companies
  • Figure 106: Protagonist Therapeutics, Inc: Overall Financials, 2018-2020
  • Figure 107: Protagonist Therapeutics, Inc: Overall R&D Expenditure, 2018-2020
  • Figure 108: Protagonist Therapeutics, Inc: Pipeline Products R&D Expenditure, 2018-2020
  • Figure 109: Protagonist Therapeutics, Inc: SWOT Analysis
  • Figure 110: Santhera Pharmaceuticals Holding: Product Portfolio
  • Figure 111: Santhera Pharmaceuticals Holding: Overall Financials, 2018-2020
  • Figure 112: Santhera Pharmaceuticals Holding: SWOT Analysis
  • Figure 113: Union Chimique Belge S.A.: Product Portfolio
  • Figure 114: Union Chimique Belge S.A.: Overall Financials, 2018-2020
  • Figure 115: Union Chimique Belge S.A.: Overall R&D Expenditure, 2018-2020
  • Figure 116: Union Chimique Belge S.A.: SWOT Analysis

List of Tables

  • Table 1: Properties of Conformationally Constrained Peptides
  • Table 2: Display and Selection System Employed by Companies
  • Table 3: Emerging Constrained Peptide Drugs Pipeline
  • Table 4: Zilucoplan Phase II Baseline Characteristics Results
  • Table 5: Selected Clinical Data Comparison between Zilucoplan and Soliris
  • Table 6: Pharmacokinetic Profile of BT1718
  • Table 7: Impact of COVID-19 on Constrained Peptide Drugs Companies
  • Table 8: Regulatory Scenario of Constrained Peptides
  • Table 9: Funding by Private Companies
  • Table 10: Bicycle Therapeutics, PLC: Overall Product Portfolio
  • Table 11: Protagonist Therapeutics, Inc: Overall Product Portfolio
  • Table 12: Pepscan Therapeutics B.V.: Product Portfolio
  • Table 13: Pepticom Ltd.: Product Portfolio
  • Table 14: PeptiDream, Inc.: Product Portfolio
  • Table 15: CPC Scientific Inc.: Product Portfolio
  • Table 16: Figure: Creative Peptides: Product Portfolio
  • Table 17: Bio-Synthesis Inc: Product Portfolio